Article
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
The New England journal of medicine - 24 Jun 2010
Maemondo Makoto, Inoue Akira, Kobayashi Kunihiko, Sugawara Shunichi, Oizumi Satoshi, Isobe Hiroshi, Gemma Akihiko, Harada Masao, Yoshizawa Hirohisa, Kinoshita Ichiro, Fujita Yuka, Okinaga Shoji, Hirano Haruto, Yoshimori Kozo, Harada Toshiyuki, Ogura Takashi, Ando Masahiro, Miyazawa Hitoshi, Tanaka Tomoaki, Saijo Yasuo, Hagiwara Koichi, Morita Satoshi, Nukiwa Toshihiro
Abstract excerpt
BACKGROUND: Non-small-cell lung cancer with sensitive mutations of the epidermal growth factor receptor (EGFR) is highly responsive to EGFR tyrosine kinase inhibitors such as gefitinib, but little is known about how its efficacy and safety profile compares with that of standard chemotherapy. METH...
Topics
- Aged
- Antineoplastic Agents
- Antineoplastic Combined Chemotherapy Protocols
- Carboplatin
- Carcinoma, Non-Small-Cell Lung
- ErbB Receptors
- Female
- Gefitinib
- Genes, erbB-1